Abstract
Background Atrial fibrillation (AF) is associated with a five-fold increased risk of ischemic stroke. A portion of this risk is heritable, however current risk stratification tools (CHA2DS2-VASc) don’t include family history or genetic risk. We hypothesized that we could improve ischemic stroke prediction in patients with AF by incorporating polygenic risk scores (PRS).
Objectives To construct and test a PRS to predict ischemic stroke in patients with AF, both independently and integrated with clinical risk factors.
Methods Using data from the largest available GWAS in Europeans, we combined over half a million genetic variants to construct a PRS to predict ischemic stroke in patients with AF. We externally validated this PRS in independent data from the UK Biobank (UK Biobank), both independently and integrated with clinical risk factors.
Results The integrated PRS and clinical risk factors risk tool had the greatest predictive ability. Compared with the currently recommended risk tool (CHA2DS2-VASc), the integrated tool significantly improved net reclassification (NRI: 2.3% (95%CI: 1.3% to 3.0%)), and fit (χ2 P =0.002). Using this improved tool, >115,000 people with AF would have improved risk classification in the US. Independently, PRS was a significant predictor of ischemic stroke in patients with AF prospectively (Hazard Ratio: 1.13 per 1 SD (95%CI: 1.06 to 1.23))). Lastly, polygenic risk scores were uncorrelated with clinical risk factors (Pearson’s correlation coefficient: −0.018).
Conclusions In patients with AF, there appears to be a significant association between PRS and risk of ischemic stroke. The greatest predictive ability was found with the integration of PRS and clinical risk factors, however the prediction of stroke remains challenging.
Competing Interest Statement
EA founder, advisor Personalis founder, advisor Deepcell advisor SequenceBio advisor Foresite Labs advisor Apple
Funding Statement
The lead author (JOS) was supported by an NIH T32 grant, otherwise, there is no specific funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank received ethical approval from the National Health Service National Research Ethics Service North West
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The UK Biobank data is available upon application. We plan to publish our polygenic risk score at http://www.pgscatalog.org/ upon publication.
Abbreviations
- CHA2DS2-VASc
- Acronym of the currently recommended tool for the risk stratification of ischemic stroke in patients with AF. C = Congestive Heart Failure, H = Hypertension, A2 =Age (over 65 or over 75), D = Diabetes Mellitus, S = Stroke, V = Vascular Disease, S = Sex
- CHA2DS2-VASc -G
- A proposed term for the integrated genetic and clinical risk stratification tool, where G = Polygenic risk score.
- GWAS
- Genome-wide association study
- AF
- Atrial Fibrillation
- SNV
- Single nucleotide variant (polymorphism)
- PRS
- Polygenic risk score
- SD
- Standard deviation
- NRI
- Net reclassification index
